CARsgen Announces Investigational CAR-T Therapy CT053 Granted PRIME Eligibility by the European Medicines Agency

CARsgen Therapeutics Receives US FDA Orphan Drug Designation For Fully Human Anti-BCMA (B Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cells For The Treatment Of Multiple Myeloma

CARsgen Therapeutics Receives IND Clearance for BCMA-CAR T cells from the U.S. FDA

CARsgen Therapeutics Receives IND Clearance for BCMA-CAR T cells from the NMPA

CARsgen Therapeutics Receives IND Clearance for GPC3-CAR T cells from the NMPA

CARsgen Presents Preliminary Results of CAR-BCMA T Cell Therapy at ASH 2018

CARsgen Appoints Dr. Hong MA as Senior Vice President of Clinical Development

CARsgen Completed $60 Million Pre-C Financing Framework Agreements

CARsgen Launches First-in-Class Anti-Claudin18.2 CAR-T Clinical Trial

CARsgen Therapeutics Joins The Alliance for Regenerative Medicine